The impact of the SARS‐CoV‐2 infection, with special reference to the hematological setting

Sica, Antonello; Casale, Danilo; Rossi, Giovanni A.; Casale, Beniamino; Ciccozzi, Massimo; Fasano, Morena; Sagnelli, Caterina; Sagnelli, Evangelista; Papa, Alfonso

doi:10.1002/jmv.26197

Cited by 27 publications

(32 citation statements)

References 90 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although there are reports about the prevalence of cancer among COVID-19 patients, the data about the prevalence of hematological malignancies among T A B L E 1 Demographic and clinical characteristics of the patients the control group. This finding supports the hypothesis of the high probability of immunopathogenic damage due to a cytokine storm because of the increased risk of an immunological hyperactivation induced by SARS-CoV-2 in hematological malignancies involving T lymphocytes, natural killer cells, histiocytes and antigen-presenting cells 17.…”

supporting

confidence: 88%

The outcome of COVID‐19 in patients with hematological malignancy

Yiğenoğlu

Ata

Altuntaş

et al. 2020

Journal of Medical Virology

103

112

View full text Add to dashboard Cite

Introduction In this study, we aim to report the outcome of COVID‐19 in patients with hematological malignancy in Turkey. Method The data of laboratory‐confirmed 188,897 COVID‐19 patients diagnosed between March 11, 2020 and June 22, 2020 included in the Republic of Turkey, Ministry of Health database were analyzed retrospectively. All of the COVID‐19 patients with hematological malignancy (n=740) were included in the study and an age, gender and comorbidity matched COVID‐19 patients without cancer (n=740) at 1:1 ratio was used for comparison. Results Non Hodgkin lymphoma (30.1%), myelodysplastic syndrome (19.7%), myeloproliferative neoplasm (15.7%), were the most common hematological malignancies. The rates of severe and critical disease were significantly higher in patients with hematological malignancy compared to the patients without cancer (p=0.001). The rates of hospital and intensive care unit (ICU) admission were higher in patients with hematological malignancy compared to the patients without cancer (p=0.023, p=0.001, respectively). The length of hospital stay and ICU stay were similar between groups (p=0.7, p=0.3; retrospectively). The rate of mechanical ventilation (MV) support was higher in patients with hematological malignancy compared to the control group (p=0.001). The case fatality rate (CFR) was 13.8% in patients with hematological malignancy, and it was 6.8% in the control group (p=0.001). Conclusion This study reveals that there is an increased risk of COVID‐19 related serious events (ICU admission, MV support or death) in patients with hematological malignancy compared to COVID‐19 patients without cancer and supports high vulnerability of patients with hematological malignancy in the current pandemic. This article is protected by copyright. All rights reserved.

show abstract

supporting

confidence: 88%

The outcome of COVID‐19 in patients with hematological malignancy

Yiğenoğlu

Ata

Altuntaş

et al. 2020

Journal of Medical Virology

103

112

View full text Add to dashboard Cite

show abstract

“…The early presentation of COVID-19 infection is typically non-specific. Among symptomatic patients, about 80% showed a mild clinical course [ 10 ] characterized by a dry cough, sore throat, low-grade fever, or malaise; in 20% of cases, the general condition worsened in about seven days from the beginning of the symptoms, culminating in respiratory failure [ 11 , 12 ].…”

Section: Introductionmentioning

confidence: 99%

Clinical Presentation of COVID-19: Case Series and Review of the Literature

Macera¹,

Angelis²,

Sagnelli³

et al. 2020

IJERPH

Self Cite

View full text Add to dashboard Cite

COVID-19 infection has a broad spectrum of severity ranging from an asymptomatic form to a severe acute respiratory syndrome that requires mechanical ventilation. Starting with the description of our case series, we evaluated the clinical presentation and evolution of COVID-19. This article is addressed particularly to physicians caring for patients with COVID-19 in their clinical practice. The intent is to identify the subjects in whom the infection is most likely to evolve and the best methods of management in the early phase of infection to determine which patients should be hospitalized and which could be monitored at home. Asymptomatic patients should be followed to evaluate the appearance of symptoms. Patients with mild symptoms lasting more than a week, and without evidence of pneumonia, can be managed at home. Patients with evidence of pulmonary involvement, especially in patients over 60 years of age, and/or with a comorbidity, and/or with the presence of severe extrapulmonary manifestations, should be admitted to a hospital for careful clinical-laboratory monitoring.

show abstract

“…All patients were evaluated with ECOG Performance Status (PS). Patients, according to the CARE guidelines, underwent physical examination, routine blood chemistry tests, and serum markers of HBV, HCV, and HIV infections (by commercial immunoenzymatic assays) (36)(37)(38)(39)(40)(41)(42). To reduce the risk of infection, the SCS apparatus was implanted in a single session (One Shoot technique).…”

Section: Methodsmentioning

confidence: 99%